Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 5,000 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the insider owned 52,324 shares of the company’s stock, valued at $4,185,920. The trade was a 8.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rahul Khara also recently made the following trade(s):

• On Friday, June 26th, Rahul Khara sold 851 shares of Disc Medicine stock. The shares were sold at an average price of $75.00, for a total transaction of $63,825.00.
• On Monday, June 29th, Rahul Khara sold 1,649 shares of Disc Medicine stock. The shares were sold at an average price of $75.00, for a total transaction of $123,675.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON remained flat at $77.44 during midday trading on Friday. 307,549 shares of the company were exchanged, compared to its average volume of 587,108. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average is $73.44 and its two-hundred day moving average is $69.73. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The firm has a market capitalization of $2.96 billion, a PE ratio of -11.77 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. As a group, sell-side analysts expect that Disc Medicine, Inc. will post -6.62 EPS for the current year.

Institutional Trading of Disc Medicine

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Disc Medicine during the 2nd quarter valued at about $180,502,000. RA Capital Management L.P. grew its position in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after acquiring an additional 399,026 shares in the last quarter. Vanguard Group Inc. increased its stake in Disc Medicine by 22.1% during the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after acquiring an additional 319,621 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock worth $134,839,000 after acquiring an additional 371,576 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after purchasing an additional 828,248 shares during the period. 83.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Wedbush restated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. HC Wainwright lifted their price objective on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday. Morgan Stanley upped their price objective on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Finally, Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $106.00.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.